EC Number   |
Application |
Reference |
|---|
   1.1.1.146 | analysis |
high-throughput screening for potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I |
691284 |
| 1.1.1.146 | analysis |
use of microdialysis sampling coupled with liquid chromatography/electrospray ionization mass spectrometry to study 11beta-hydroxysteroid dehydrogenase type 1 catalyzed conversion of stable-isotope-labeled cortisone to cortisol in liver microsome. Results show species-specific reaction profiles, with a five times higher coversion rate in dog than in human and monkey liver microsome |
690401 |
| 1.1.1.146 | drug development |
11beta-HSD1 will significantly contribute to the biotransformation of oracin in humans. The microsomal carbonyl reductase has a great potential to significantly impair the chemotherapy with the anticancer drug oracin |
701324 |
| 1.1.1.146 | drug development |
isozyme 11beta-HSD1 is a target in treatment of metabolic diseases such as diabetes mellitus type 2 or obesity |
670258 |
| 1.1.1.146 | medicine |
11beta-HSD1 inhibition may be a valid target for the treatment of diabetes |
699469 |
| 1.1.1.146 | medicine |
11beta-HSD1 is a drug target for treatment of insulin resistance, diabetes and cardiovascular disease |
700178 |
| 1.1.1.146 | medicine |
activation of cortisol by 11beta-hydroxysteroid dehydrogenase in granulosa cells increases with follicle development but is significantly decreased in ovarion cysts |
695089 |
| 1.1.1.146 | medicine |
at baseline, mRNA levels are similar in skeletal muscle of diabetic and control sugjects for 11beta-HSD1, 11beta-HSD2, and hexose-6-phosphate dehydrogenase. 11beta-HSD1 activity is reduced in diabetic subjects, while 11beta-HSD2 activity is increased. After application of dexamethasone, 11beta-HSD1 mRNA increases in both groups, whereas 11beta-HSD2 mRNA decreases. 11beta-HSD1 activity increases in diabetic subjects, but not in controls, whereas 11beta-HSD2 activity does not change in either group; mRNA levels are similar in diabetic and control subjects for 11beta-hydroxysteroid dehydrogenase 1 and 11beta-hydroxysteroid dehydrogenase 2. 11beta-Hydroxysteroid dehydrogenase 2-activity is higher in diabetic patients. After treatment with dexamethasone, 11beta-hydroxysteroid dehydrogenase 1-mRNA increases in both groups, whereas 11beta-hydroxysteroid dehydrogenase 2-mRNA decreases. 11beta-Hydroxysteroid dehydrogenase 1-activity increases in diabetic patients, but not in control, whereas 11beta-hydroxysteroid dehydrogenase 2-activity does not change in either group |
687961 |
| 1.1.1.146 | medicine |
changes in ovarian cortisol metabolism are accompanied by corresponding changes in the levels of paracrine inhibitors of 11beta-hydroxysteroid dehydrogenase within growing ovarian follicles and cysts |
695089 |
| 1.1.1.146 | medicine |
curcumin is inhibitory to isoform 11beta-HSD1 in intact cells with IC50 value of 5.79 microM, competitive. Treatment with curcumin reduces serum glucose, cholesterol, triglyceride, low density lipoprotein levels in high-fat-diet-induced obese rats |
726314 |
